You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 7,446,124

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,446,124

Title:	Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
Abstract:	Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
Inventor(s):	Kirkpatrick; Lynn (Tucson, AZ), Powis; Garth (Tucson, AZ), Wipf; Peter (Pittsburgh, PA)
Assignee:	Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ)
Application Number:	11/178,553
Patent Claims:	1. A method of treating cancer comprising administering to a subject a pharmaceutically effective amount of a compound selected from ##STR00011## wherein Y is a heteroatom selected from nitrogen and sulfur and R1 and R2 are independently selected from an unsaturated alkyl, non-linear alkyl, cyclic alkyl, and substituted alkyl, and a cancer chemotherapeutic agent. 2. The method of claim 1, wherein said R1 and R2 are a disubstituted alkyl. 3. The method of claim 1, wherein said cancer chemotherapeutic agent is selected from the group consisting of a cytotoxic agent and an anti-tumor targeting agent. 4. The method of claim 3, wherein said cytotoxic agent is selected from the group consisting of gemeitabine, paclitaxel, and cisplatin. 5. The method of claim 3, wherein said anti-tumor targeting agent is selected from the group consisting of gefitinib, erlotinib, trastuzumab, cetuximab and bevacizumab. 6. The method of claim 1, wherein said compound is selected from: ##STR00012## 7. The method of claim 1, wherein said compound is: ##STR00013## 8. The method of claim 1, wherein said compound is: ##STR00014## 9. The method of claim 1, wherein said compound is administered orally. 10. The method of claim 1, wherein said compound is administered intravenously. 11. The method of claim 1, wherein said compound is ##STR00015## and said chemotherapeutic agent is gefitinib. 12. The method of claim 1, wherein said compound is ##STR00016## and said chemotherapeutic agent is bevacizumab. 13. The method of claim 1, wherein said compound is ##STR00017## and said chemotherapeutic agent is gefitinib. 14. The method of claim 1, wherein said compound is ##STR00018## and said chemotherapeutic agent is bevacizumab. 15. The method of claim 1, further comprising administering an antihyperglycemic agent. 16. A composition comprising a compound of the formula selected from ##STR00019## wherein Y is a heteroatom selected from nitrogen and sulfur and R1 and R2 are independently selected from an unsaturated alkyl, non-linear alkyl, cyclic alkyl, and substituted alkyl, and a cancer chemotherapeutic agent. 17. The composition of claim 16, wherein said compound is ##STR00020## 18. The composition of claim 16, wherein said compound is ##STR00021## 19. A method of treating cancer comprising administering to a subject a pharmaceutically effective amount of a compound selected from ##STR00022## wherein Y is a heteroatom selected from nitrogen and sulfur and R1 and R2 are indepdently selected from an unsaturated alkyl, non-linear alkyl, cyclic alkyl, and substituted alkyl, and radiation. 20. The method of claim 19, wherein said R1 and R2 are a disubstituted alkyl. 21. The method of claim 19, wherein said compound is selected from ##STR00023## 22. The method of claim 19, wherein said compound is: ##STR00024## 23. The method of claim 19, wherein said compound is: ##STR00025## 24. The method of claim 19, wherein said compound is administered orally. 25. The method of claim 19, wherein said compound is administered intravenously.

Details for Patent 7,446,124

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2024-07-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2024-07-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2024-07-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2024-07-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.